- Home
- SN vs GMAB Comparison
SN vs GMAB Comparison
Compare SN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SN
- GMAB
- Stock Information
- Founded
- SN 1993
- GMAB 1999
- Country
- SN United States
- GMAB Denmark
- Employees
- SN N/A
- GMAB N/A
- Industry
- SN
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SN
- GMAB Health Care
- Exchange
- SN Nasdaq
- GMAB Nasdaq
- Market Cap
- SN 15.1B
- GMAB 15.0B
- IPO Year
- SN N/A
- GMAB N/A
- Fundamental
- Price
- SN $100.93
- GMAB $20.59
- Analyst Decision
- SN Strong Buy
- GMAB Buy
- Analyst Count
- SN 9
- GMAB 8
- Target Price
- SN $116.39
- GMAB $43.00
- AVG Volume (30 Days)
- SN 2.1M
- GMAB 1.5M
- Earning Date
- SN 10-31-2024
- GMAB 11-06-2024
- Dividend Yield
- SN N/A
- GMAB N/A
- EPS Growth
- SN 116.23
- GMAB 14.35
- EPS
- SN 2.55
- GMAB 10.80
- Revenue
- SN $5,118,951,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- SN $29.25
- GMAB $30.31
- Revenue Next Year
- SN $12.10
- GMAB $16.49
- P/E Ratio
- SN $39.54
- GMAB $18.52
- Revenue Growth
- SN 26.12
- GMAB 17.75
- 52 Week Low
- SN $43.31
- GMAB $20.50
- 52 Week High
- SN $112.93
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- SN 48.04
- GMAB 25.31
- Support Level
- SN $100.48
- GMAB $21.90
- Resistance Level
- SN $105.75
- GMAB $23.47
- Average True Range (ATR)
- SN 4.42
- GMAB 0.45
- MACD
- SN 0.21
- GMAB -0.12
- Stochastic Oscillator
- SN 55.51
- GMAB 3.03
About SN SharkNinja Inc.
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.